imotuzumab- Head and neck cancer
- Conditions
- Squamous cell carcinoma of head and neck in advanced stages.
- Registration Number
- RPCEC00000089
- Lead Sponsor
- Center of Molecular Immunology(CIM)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- Not specified
1.Age greater than or equal to 18 years. 2.Life expectancy of at least 12 weeks. 3.General status ECOG 0-2. 4.Patients give their consent to participate in the study in writing.
1.Patient at the time of inclusion is receiving another investigational drug. 2.Pregnancy,postpartum or breastfeeding. 3.History of hypersensitivity to any of the components of the pharmaceutical formulation of Nimotuzumab. 4.Presence of a second primary tumor, except basal or squamous cell carcinoma of the skin and neck carcinoma in situ treated.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.